Study of Pretargeted Radioimmunotherapy of a Anti-CEA Bispecific Antibody and Lu177-labeled Peptide in Colorectal Cancer

Pretherapy cycle with IMP-288 labeled In111.

Inclusion criteria

• Patients with CEA expressing advanced colorectal tumors for which no standard treatment is available
• WHO performance status: 0 or 1
• Having normal hematological function: Neutrophils > 1.5 x 109/l; Platelet count > 150 x 109/l, without transfusion during the previous month; Hemoglobin > 5.6 mmol/l
• Total bilirubin < 2 x upper limit of normal (ULN)
• ASAT, ALAT < 3 x ULN
• Serum creatinine < 2 x ULN
• Cockcroft clearance > 50 ml/min
• Negative pregnancy test for women of child¬bearing potential (urine or serum)
• Age over 18 years
• Ability to provide written informed consent

Exclusion criteria

• Known metastases to the brain
• Chemotherapy, external beam radiation or immunotherapy within 4 weeks prior to study. Limited field external beam radiotherapy to prevent pathological fractures is allowed, when unirradiated, evaluable lesions elsewhere are present.
• Prior angiogenesis inhibitors within 4 weeks; bevacizumab within 8 weeks
• Cardiac disease with New York Heart Association classification of III or IV
• Patients who are pregnant, nursing or of reproductive potential and are not practicing an effective method of contraception
• Any unrelated illness, e.g. active infection, inflammation, medical condition or laboratory abnormalities, which in the judgement of the investigator will significantly affect patients' clinical status
• Life expectancy shorter than 6 months.